Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
First Patient Treated in Phase 2 GvHD Trial 2024-03-05 10:08
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:19
Hybribio Calls for Raising International HPV Awareness 2024-03-04 18:47
Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting 2024-03-04 16:53
Thermo Fisher Scientific to Inaugurate New Office, Marking Milestone Expansion in Indonesia 2024-03-01 10:30
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia 2024-03-01 08:00
Metabolon Unveils New Integrated Bioinformatics Platform 2024-02-29 20:58
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency 2024-02-29 17:40
MGI Tech & Juntendo University: Changing the Landscape and Unlocking Answers for Patients with Rare Diseases 2024-02-29 09:00
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease 2024-02-28 21:32
RRD International is now RRD Biopharma Development 2024-02-28 21:00
BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions 2024-02-28 02:30
New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks 2024-02-27 17:00
Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China 2024-02-27 16:09
Sengenics Corporation Announces Key Distributor in China 2024-02-27 08:30
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis 2024-02-27 07:14
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases 2024-02-27 01:06
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 2024-02-22 08:59
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA 2024-02-21 12:26
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine 2024-02-21 09:00
1 5 6 7 8 9 210